IFIH1 and dermatomyositis: By blocking the type I interferon signaling pathway, which is central to the pathogenesis of DM, they have shown remarkable efficacy in treating refractory cutaneous disease and, very relevantly, in managing ILD, including the rapidly progressive forms associated with the anti-MDA5 antibody [38,39].